YD Bio Ltd

YD Bio Ltd has a fully diluted share count of 70.83 million shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible securities. The company's market price is $5.06 per share, resulting in a market capitalization of $358.41 million. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability metrics are not available in the current dataset, and no industry-specific preferred metrics are provided for comparison. As a result, it is not possible to assess the company's profitability or returns relative to industry benchmarks. The company's revenue concentration and geographic exposure are not disclosed in the available data. There is no information on revenue by segment or region, making it difficult to evaluate the diversification of its business. Growth trajectory is also unclear, as no numeric deltas or revenue history are provided in the outlook. The absence of forward-looking guidance or historical performance data limits the ability to assess the company's growth potential. Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. Additionally, the lack of disclosed balance-sheet data and going-concern language raises concerns about the company's financial health. Dilution risk is currently rated as low, but this is based on the absence of dilutive instruments rather than active management of capital structure. Recent events, including filings and transcripts, are not available in the current dataset. The company's financial and operational disclosures are limited, which may affect the ability to monitor its performance and strategic direction.